S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
NASDAQ:ABUS

Arbutus Biopharma (ABUS) Stock Price, News & Analysis

$2.60
+0.11 (+4.42%)
(As of 03/27/2024 ET)
Today's Range
$2.48
$2.60
50-Day Range
$2.32
$2.92
52-Week Range
$1.69
$3.14
Volume
830,090 shs
Average Volume
641,063 shs
Market Capitalization
$466.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Arbutus Biopharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
92.3% Upside
$5.00 Price Target
Short Interest
Bearish
2.30% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.47mentions of Arbutus Biopharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.39) to ($0.43) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.45 out of 5 stars

Medical Sector

795th out of 939 stocks

Pharmaceutical Preparations Industry

372nd out of 435 stocks

ABUS stock logo

About Arbutus Biopharma Stock (NASDAQ:ABUS)

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

ABUS Stock Price History

ABUS Stock News Headlines

ABUS Jan 2025 7.000 call
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Q4 2023 Arbutus Biopharma Corp Earnings Call
ABUS Jun 2024 3.000 put
ABUS Apr 2024 6.000 call
ABUS Apr 2024 3.000 call
ABUS Sep 2024 3.000 call
Arbutus Biopharma Corporation (ABUS)
Arbutus Biopharma Corporation (ABUS)
Chardan Capital Reaffirms Their Buy Rating on Arbutus Biopharma (ABUS)
See More Headlines
Receive ABUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ABUS
Employees
73
Year Founded
1992

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$6.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+92.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-72,850,000.00
Net Margins
-401.57%
Pretax Margin
-401.57%

Debt

Sales & Book Value

Annual Sales
$18.14 million
Book Value
$0.63 per share

Miscellaneous

Free Float
169,799,000
Market Cap
$466.67 million
Optionable
Optionable
Beta
2.04

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Michael J. Sofia Ph.D. (Age 66)
    Chief Scientific Officer
    Comp: $628.43k
  • Mr. David C. Hastings CPA (Age 63)
    CFO & Chief Accounting Officer
    Comp: $647.1k
  • Ms. Lisa M. Caperelli
    Vice President of Investor Relations
  • Mr. J. Christopher Naftzger BA (Age 57)
    Esq., J.D., General Counsel & Chief Compliance Officer
  • Ms. Shannon Briscoe SPHR
    Vice President of Human Resources
  • Dr. Karen Sims M.D.
    Ph.D., Chief Medical Officer
  • Mr. R. Hector Mackay-Dunn B.A. (Age 73)
    J.D., L.L.B., Q.C., Secretary

ABUS Stock Analysis - Frequently Asked Questions

Should I buy or sell Arbutus Biopharma stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ABUS shares.
View ABUS analyst ratings
or view top-rated stocks.

What is Arbutus Biopharma's stock price target for 2024?

3 brokers have issued 1-year target prices for Arbutus Biopharma's shares. Their ABUS share price targets range from $4.00 to $6.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 92.3% from the stock's current price.
View analysts price targets for ABUS
or view top-rated stocks among Wall Street analysts.

How have ABUS shares performed in 2024?

Arbutus Biopharma's stock was trading at $2.50 on January 1st, 2024. Since then, ABUS stock has increased by 4.0% and is now trading at $2.60.
View the best growth stocks for 2024 here
.

When is Arbutus Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ABUS earnings forecast
.

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Co. (NASDAQ:ABUS) announced its earnings results on Thursday, February, 29th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.12). The biopharmaceutical company earned $2.15 million during the quarter, compared to analyst estimates of $4.74 million. Arbutus Biopharma had a negative trailing twelve-month return on equity of 57.82% and a negative net margin of 401.57%. During the same quarter in the previous year, the firm posted ($0.14) earnings per share.

What ETFs hold Arbutus Biopharma's stock?

ETFs with the largest weight of Arbutus Biopharma (NASDAQ:ABUS) stock in their portfolio include Morningstar US Small Growth (MSGR) and iShares Genomics Immunology and Healthcare ETF (IDNA).Amplify Treatments, Testing and Advancements ETF (GERM).

What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO?

6 employees have rated Arbutus Biopharma Chief Executive Officer Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among the company's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arbutus Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.57%), Vanguard Group Inc. (3.34%), FourWorld Capital Management LLC (0.65%), BNP Paribas Financial Markets (0.17%), UBS Group AG (0.08%) and Clear Harbor Asset Management LLC (0.08%).
View institutional ownership trends
.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ABUS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners